Technical Analysis for CALA - Calithera Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Up | Up |
| Historical CALA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 50 DMA | Bullish | 0.00% | |
| Expansion Pivot Buy Setup | Bullish Swing Setup | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Stochastic Buy Signal | Bullish | 10.73% | |
| Lower Bollinger Band Walk | Weakness | 10.73% | |
| Lower Bollinger Band Touch | Weakness | 10.73% | |
| Oversold Stochastic | Weakness | 10.73% | |
| 50 DMA Resistance | Bearish | 8.10% | |
| MACD Bearish Centerline Cross | Bearish | 8.10% | |
| Lower Bollinger Band Walk | Weakness | 8.10% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Resistance | 1 day ago |
| Rose Above 10 DMA | 1 day ago |
| 60 Minute Opening Range Breakout | 1 day ago |
| Rose Above 50 DMA | 1 day ago |
| Up 5% | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/09/2021
Calithera Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Its lead product candidate includes CB-839, an inhibitor of glutaminase, which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. The company was founded in 2010 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Solid Tumors Treatment Of Cancer Oncology Lymphoma Tumor Hematology Multiple Myeloma Targeted Therapy Metabolism Anatomical Pathology Phosphoinositide 3 Kinase Inhibitor Leukemias Glutaminase
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Immunology Solid Tumors Treatment Of Cancer Oncology Lymphoma Tumor Hematology Multiple Myeloma Targeted Therapy Metabolism Anatomical Pathology Phosphoinositide 3 Kinase Inhibitor Leukemias Glutaminase
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.185 |
| 52 Week Low | 1.78 |
| Average Volume | 562,576 |
| 200-Day Moving Average | 2.70 |
| 50-Day Moving Average | 2.16 |
| 20-Day Moving Average | 2.27 |
| 10-Day Moving Average | 2.21 |
| Average True Range | 0.12 |
| ADX | 18.54 |
| +DI | 22.26 |
| -DI | 22.50 |
| Chandelier Exit (Long, 3 ATRs) | 2.12 |
| Chandelier Exit (Short, 3 ATRs) | 2.36 |
| Upper Bollinger Bands | 2.53 |
| Lower Bollinger Band | 2.02 |
| Percent B (%b) | 0.49 |
| BandWidth | 22.33 |
| MACD Line | -0.01 |
| MACD Signal Line | 0.02 |
| MACD Histogram | -0.0298 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.56 | ||||
| Resistance 3 (R3) | 2.52 | 2.40 | 2.51 | ||
| Resistance 2 (R2) | 2.40 | 2.32 | 2.41 | 2.49 | |
| Resistance 1 (R1) | 2.33 | 2.28 | 2.37 | 2.37 | 2.48 |
| Pivot Point | 2.21 | 2.21 | 2.22 | 2.22 | 2.21 |
| Support 1 (S1) | 2.14 | 2.13 | 2.18 | 2.18 | 2.06 |
| Support 2 (S2) | 2.02 | 2.09 | 2.03 | 2.05 | |
| Support 3 (S3) | 1.95 | 2.02 | 2.03 | ||
| Support 4 (S4) | 1.99 |
